<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260823070769N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-08-31</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Effect of Shockwave Therapy Versus Ultrasound on Muscle Spasticity After Stroke</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the Effects of Extracorporeal Shockwave Therapy and Pulsed Ultrasound on Spasticity neurophysiological and Functional outcomes in Patients with Stroke</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-09-15</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>24</target_size>
      <recruitment_status>Pending</recruitment_status>
      <url>https://irct.ir/trial/92783</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: A total of 30 patients will be randomly assigned into two groups of 15 participants each: the Extracorporeal Shockwave Therapy (ESWT) group and the Pulsed Ultrasound (PUS) group. Both groups will receive treatment 3 sessions per week. Randomization will be performed using a simple randomization method with sealed, opaque envelopes describing the treatment groups. In the first step, the name of each intervention will be written on 15 papers (equal to the sample size of each group) and placed in sealed envelopes. The envelopes will then be mixed, and at the first treatment session, the therapist will draw one envelope randomly to determine the participant’s assigned group and initiate the treatment accordingly, Blinding description: This study is a single-blinded randomized controlled trial. Due to the nature of the physiotherapy interventions, blinding of the therapist and participants is not possible. However, the outcome assessor is blinded to group allocation. All assessments are performed by an independent assessor who is not involved in treatment and is unaware of the intervention received by participants. Randomization and allocation concealment are performed to minimize assessment bias.</study_design>
      <phase>4</phase>
      <hc_freetext>lower limb spasticity after stroke.</hc_freetext>
      <i_freetext>Intervention 1: Shock wave group  patients will receive 3 sessions of radial  extracorporeal shock wave therapy  (rESWT)(33, 34) (energy: 60 mJ) with a head applicator 15 mm, 2000 shots, frequency 5 Hz, energy density of 60mj (1 bar), energy applied 0.340 mJ/mm²on myotendinous junction and mid portion of gastrocnemius muscle belly. Intervention 2: Intervention group: Ultrasound group . patients will receive 3 sessions of pulsed ultrasound  on = 1 ms,  off = 9 ms; Duty cycle = 10%) with the following protocol: frequency 1 MHz, intensity 1.5 W/cm², Area of applicator: 5 cm², duration 10 minutes) on the gastrocnemius muscle belly.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Compliance with the rules</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hussein abdul razzaq jabbar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>karbala .teachers quarter</address>
        <city>karbala</city>
        <country1>Iraq</country1>
        <zip>3292572210</zip>
        <telephone>+964 771 442 5820</telephone>
        <email>husseinsarafei@gmail.com</email>
        <affiliation>center for hereditary blood diseases</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Noureddin Nakhostin Ansari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Piche Shemiran, Enghelab Ave.,Tehran</address>
        <city>tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1148965111</zip>
        <telephone>+98 21 7753 5132</telephone>
        <email>nakhostin@tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iraq</country2>
    </countries>
    <criteria>
      <inclusion_criteria>First-ever stroke. .7
.Stroke duration of at least 6 months and less than 48 months
Age 40-70 years.
.Ankle plantar flexor MMAS score ≥1
Be able to walk independently
Stable vital signs
constant drug protocol doses</inclusion_criteria>
      <agemin>40 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Sensation deficits in the foot area
.	Currently being treated for spasticity
.	Wound or infection in the affected lower limb
.	Ultrasound and shockwave contraindications.
Radial extracorporeal shock wave therapy (rESWT) contraindications (pregnancy, On major )
vessels and nerves, Pacemaker or other implanted devices, Open wounds, Joint
Fixed ankle joint contracture .
History of Botox . alcohol or phenol block  treatments within previous 6 months ago
Severe pain with rSWET</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G81.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Spastic hemiplegia</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Shock wave group  patients will receive 3 sessions of radial  extracorporeal shock wave therapy  (rESWT)(33, 34) (energy: 60 mJ) with a head applicator 15 mm, 2000 shots, frequency 5 Hz, energy density of 60mj (1 bar), energy applied 0.340 mJ/mm²on myotendinous junction and mid portion of gastrocnemius muscle belly.</i_keyword>
      <i_keyword>Intervention group: Ultrasound group . patients will receive 3 sessions of pulsed ultrasound  on = 1 ms,  off = 9 ms; Duty cycle = 10%) with the following protocol: frequency 1 MHz, intensity 1.5 W/cm², Area of applicator: 5 cm², duration 10 minutes) on the gastrocnemius muscle belly</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Severity of spasticity assessed using the MMAS. Timepoint: Primary outcome will be measured at baseline before treatment (T0), immediately after the third treatment session (T1), one week after treatment completion (T2), and one month after treatment completion (T3). Method of measurement: The patient will be positioned in supine lying with the lower limbs extended, the head in midline, and the upper limbs resting alongside the trunk. The examiner will stand on the side being tested, placing one hand under the ball of the foot and the other hand stabilizing the limb around the ankle joint. The ankle joint will then be moved from maximum plantar flexion into maximum possible dorsiflexion within approximately one second. The severity of spasticity will be scored from 0 to 4 based on the resistance encountered during passive movement of the ankle plantar flexor muscles, according to the MMAS criteria.</prim_outcome>
      <prim_outcome>Ankle dorsiflexion range of motion (ROM). Timepoint: Primary outcome will be measured at baseline before treatment (T0), immediately after the third treatment session (T1), one week after treatment completion (T2), and one month after treatment completion (T3). Method of measurement: A standard ankle goniometer will be used to assess dorsiflexion range of motion. The patient will be positioned supine with the knee extended and the ankle in a neutral resting position. The fixed arm of the goniometer will be aligned with the longitudinal axis of the leg, while the movable arm will be positioned along the sole of the affected foot. To measure active dorsiflexion, the patient will be instructed to dorsiflex the ankle as far as possible. The same procedure will be used to measure passive ankle dorsiflexion range of motion, except that the physiotherapist will move the ankle through the available range instead of the patient actively performing the movement.</prim_outcome>
      <prim_outcome>Functional outcome.Timed Up and Go   (TUG). Timepoint: Primary outcome will be measured at baseline before treatment (T0), immediately after the third treatment session (T1), one week after treatment completion (T2), and one month after treatment completion (T3). Method of measurement: 1.	The participant begins seated in the chair, wearing regular footwear and using their usual walking aid if needed.2.	On the command Go the participant stands up and walks at a safe, comfortable pace toward the 3-meter mark.3.	After reaching the mark, the participant turns around, walks back to the chair, and sits down.4.	Timing: Start the stopwatch on the word Go and stop it when the participant’s buttocks make contact with the seat.</prim_outcome>
      <prim_outcome>Neurophysiological outcomes.H reflex recording:. Timepoint: Primary outcome will be measured at baseline before treatment (T0), immediately after the third treatment session (T1), one week after treatment completion (T2), and one month after treatment completion (T3). Method of measurement: The electromyography machine will be used to evaluate the maximal H-reflex, the maximal M-wave, and the H-reflex latency. The patient is placed in a prone position with feet off the table. bipolar recording electrodes will be placed on the apex of the triangle formed by the soleus muscle, and the stimulating electrode will be placed 4-5 cm distal from this electrode and will stimulate the posterior tibial nerve in the popliteal fossa. The electromyography (EMG) machine will be set with the band-pass filter at 5 Hz to 3 kHz, sweep speed at 5 msec/div and sensitivity at 500 µV-2 mV/div.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Passive plantar flexion torque. Timepoint: Primary outcome will be measured at baseline before treatment (T0), immediately after the third treatment session (T1), one week after treatment completion (T2), and one month after treatment completion (T3). Method of measurement: use a hand-held dynamometer to assess passive plantar flexor torque. The center of the sensitive pad of the dynamometer will be placed on the center of the metatarsal arch in alignment with the head of the third metatarsal, and a fast passive ankle dorsiflexion will be performed. The torque will be assessed. The maximum force obtained will be multiplied by the distance from the third metatarsal head to the ankle joint axis to calculate the maximum torque. Reliability and validity of ankle dynamometry have been confirmed in patients with spasticity.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-08-19</approval_date>
        <contact_name>School of Nursing and Midwifery &amp; Rehabilitation - Tehran University of Medical Sciences</contact_name>
        <contact_address>Mirkhani st.(East Nosrat), Tohid Sq. Tehran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
